ABN Amro Investment Solutions Sells 42,901 Shares of Johnson & Johnson $JNJ

ABN Amro Investment Solutions lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 31.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,693 shares of the company’s stock after selling 42,901 shares during the quarter. ABN Amro Investment Solutions’ holdings in Johnson & Johnson were worth $17,187,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank increased its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the period. Wealth Group Ltd. raised its position in Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares during the period. Finally, Sendero Wealth Management LLC lifted its stake in Johnson & Johnson by 4.2% in the second quarter. Sendero Wealth Management LLC now owns 8,353 shares of the company’s stock valued at $1,276,000 after purchasing an additional 337 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.5%

Shares of NYSE:JNJ opened at $243.37 on Friday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.35. The business’s 50 day moving average price is $217.25 and its 200-day moving average price is $196.59. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.80. The firm has a market capitalization of $586.51 billion, a price-to-earnings ratio of 22.02, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New clinical data — 12‑month pilot results for the OMNY‑AF/OMNYPULSE atrial‑fibrillation platform showed strong success, supporting J&J’s device pipeline and longer‑term growth prospects. Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study
• Positive Sentiment: High‑profile endorsement — Jim Cramer publicly praised J&J, which can lift retail sentiment and trading interest in the near term. Johnson & Johnson (JNJ) is amazing, says Jim Cramer
• Positive Sentiment: Investor interest — coverage noting hedge‑fund ownership and favorable research commentary highlights institutional demand for JNJ as a defensive, cash‑generative mega‑cap. Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?
• Neutral Sentiment: Analyst/valuation discussion — commentary (Forbes) examines whether JNJ remains attractive after a large multi‑quarter rally, noting strong fundamentals but higher expectations. This may temper upside but doesn’t change fundamentals. After A 55% Surge, Is JNJ Stock Still A Buy?
• Neutral Sentiment: Minor analyst action — Wall Street Zen cut JNJ to Hold, a modest signal that could pressure sentiment but not a major catalyst by itself. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: Legal headline risk — A Pennsylvania jury found J&J liable in a talc/ovarian‑cancer case and awarded $250,000 to the plaintiff’s family. While the award is modest, the ruling renews media focus on J&J’s long‑running talc litigation and could sustain volatility or incremental settlement exposure. Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial Philadelphia Jury Returns $250,000 Verdict Against J&J

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Wells Fargo & Company upped their target price on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. Wolfe Research raised their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.